Skip to main content

UMSOM Named as Part of NIH Infectious Disease Clinical Research Consortium

January 01, 2021

UMSOM’s CVD Plays Key Role in NIH-Funded Clinical Trial Network that Will Test New Vaccines and Treatments

The National Institute of Allergy and Infectious Diseases (NIAID), one of the National Institutes of Health, announced the establishment of the Infectious Diseases Clinical Research Consortium, a clinical trials network that will encompass the Institute’s long-standing Vaccine and Treatment Evaluation Units (VTEUs) and create a new consortium leadership group. NIAID intends to provide approximately $29 million per year for seven years for the VTEU program and its companion leadership group.

The consortium leadership group will be headed by co-principal investigators David S. Stephens, M.D., of Emory University, and Kathleen M. Neuzil, M.D., M.P.H., of the University of Maryland School of Medicine. The group will include VTEU investigators as well as scientific experts in infectious diseases who will prioritize candidate vaccines, diagnostics, therapeutics and other interventions to test in clinical trials. To respond to public health emergencies, the leadership group will have the capacity to rapidly organize and initiate clinical trials at the VTEU sites. It also will coordinate activities with VTEU sites implementing specific clinical trials and with scientific staff in the NIAID Division of Microbiology and Infectious Diseases (DMID).

Read the full story at: https://www.niaid.nih.gov/news-events/infectious-diseases-clinical-research-consortium-awards-announced

Contact

Office of Public Affairs
655 West Baltimore Street
Bressler Research Building 14-002
Baltimore, Maryland 21201-1559

Contact Media Relations
(410) 706-5260

Related stories

    Wednesday, April 05, 2023

    UM School of Medicine Researchers Chart Path Forward on Developing mRNA Vaccines for Infections Beyond COVID-19

    After helping to develop and test new mRNA technologies for COVID-19 vaccines, University of Maryland School of Medicine (UMSOM) researchers and scientists are turning their attention to utilizing this innovative technology to ward off other infectious diseases like malaria and influenza. Last month, UMSOM faculty in the Center for Vaccine Development and Global Health (CVD) launched a new clinical trial to investigate the use of mRNA technologies to create a vaccine against malaria. CVD Director Kathleen M. Neuzil, MD, MPH, FIDSA also provided commentary in the nation’s leading medical journal on the feasibility of using mRNA to develop a universal influenza vaccine that could eliminate the need for seasonal shots.


    Monday, October 21, 2019

    UM School of Medicine's Kathleen M Neuzil Elected as Member of Prestigious National Academy of Medicine

    Kathleen M. Neuzil, MD, MPH, Professor of Medicine and Pediatrics and Director of the Center for Vaccine Development and Global Health (CVD) at the University of Maryland School of Medicine (UMSOM), has been elected as a member of the National Academy of Medicine (NAM), in recognition of her pivotal research that has informed and shaped global vaccine and public health policy. Her membership was announced at the annual NAM meeting in Washington, D.C., placing her among the 2,178 U.S. members of this important organization. Membership in the Academy is considered one of the highest honors for individuals who have made major contributions to the advancement of the medical sciences, health care and public health.